SG11201908543WA - Anti-pd-l1 antibody for detecting pd-l1 - Google Patents

Anti-pd-l1 antibody for detecting pd-l1

Info

Publication number
SG11201908543WA
SG11201908543WA SG11201908543WA SG11201908543WA SG 11201908543W A SG11201908543W A SG 11201908543WA SG 11201908543W A SG11201908543W A SG 11201908543WA SG 11201908543W A SG11201908543W A SG 11201908543WA
Authority
SG
Singapore
Prior art keywords
amino acid
acid sequence
seq
antibody
detecting
Prior art date
Application number
Inventor
Satoru KONNAI
Kazuhiko Ohashi
Shiro Murata
Tomohiro Okagawa
Asami Nishimori
Naoya Maekawa
Satoshi Takagi
Yumiko Kagawa
Yasuhiko Suzuki
Chie Nakajima
Original Assignee
Univ Hokkaido Nat Univ Corp
Fuso Pharm Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Hokkaido Nat Univ Corp, Fuso Pharm Ind Ltd filed Critical Univ Hokkaido Nat Univ Corp
Publication of SG11201908543WA publication Critical patent/SG11201908543WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70532—B7 molecules, e.g. CD80, CD86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention provides an anti-PD-L1 antibody capable of staining tumor cells such as melanoma cells. An anti-PD-L1 antibody comprising (a) a light chain comprising CDR1 having the amino acid sequence of KSISKY (SEQ ID NO: 1), CDR2 having the amino acid sequence of SGS and CDR3 having the amino acid sequence of QQHNEYPLT (SEQ ID NO: 2) and (b) a heavy chain comprising CDR1 having the amino acid sequence of GYTFTDYI (SEQ ID NO: 3), CDR2 having the amino acid sequence of INPDSGGN (SEQ ID NO: 4) and CDR3 having the amino acid sequence of ARGITMMVVISHWKFDF (SEQ ID NO: 5). A composition for detecting PD-L1, comprising the above antibody as an active ingredient. A method for preparing the above antibody is also provided.
SG11201908543W 2017-03-27 2018-03-23 Anti-pd-l1 antibody for detecting pd-l1 SG11201908543WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017061389 2017-03-27
PCT/JP2018/011895 WO2018181064A1 (en) 2017-03-27 2018-03-23 Anti-pd-l1 antibody for detecting pd-l1

Publications (1)

Publication Number Publication Date
SG11201908543WA true SG11201908543WA (en) 2019-10-30

Family

ID=63675642

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201908543W SG11201908543WA (en) 2017-03-27 2018-03-23 Anti-pd-l1 antibody for detecting pd-l1

Country Status (14)

Country Link
US (2) US10865246B2 (en)
EP (1) EP3604539A4 (en)
JP (1) JP7036388B2 (en)
KR (1) KR102402398B1 (en)
CN (1) CN110418842B (en)
AU (1) AU2018242880A1 (en)
BR (1) BR112019019077A2 (en)
CA (1) CA3056045A1 (en)
MX (1) MX2019010555A (en)
MY (1) MY197497A (en)
PH (1) PH12019502023A1 (en)
RU (1) RU2758723C2 (en)
SG (1) SG11201908543WA (en)
WO (1) WO2018181064A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201908543WA (en) 2017-03-27 2019-10-30 Univ Hokkaido Nat Univ Corp Anti-pd-l1 antibody for detecting pd-l1
AR118619A1 (en) * 2019-04-10 2021-10-20 Bio Thera Solutions Ltd ANTIBODIES OF BINDING TO PD-1
WO2023219147A1 (en) * 2022-05-13 2023-11-16 塩野義製薬株式会社 Novel anti-ccr8 antibodies for detecting ccr8

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2385115A (en) 1940-11-27 1945-09-18 Mechanical Handling Sys Inc Haulaway trailer construction
JPS53106853A (en) 1977-02-28 1978-09-18 Yokohama Rubber Co Ltd Wire for reinforcing rubber wares
CA3045637A1 (en) * 2006-12-27 2008-07-10 Emory University Compositions and methods for the treatment of infections and tumors
WO2010074080A1 (en) 2008-12-22 2010-07-01 国立大学法人北海道大学 Expression vector for producing protein derived from foreign gene in large quantity using animal cells, and use thereof
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
ES2848052T3 (en) * 2012-08-03 2021-08-05 Dana Farber Cancer Inst Inc Single Agent Anti-PD-L1 and PD-L2 Dual Binding Antibodies and Methods of Use
AU2014339900B2 (en) * 2013-10-25 2019-10-24 Dana-Farber Cancer Institute, Inc. Anti-PD-L1 monoclonal antibodies and fragments thereof
US10280223B2 (en) * 2014-07-09 2019-05-07 Nippon Zenyaku Kogyo Co., Ltd. Anti-canine PD-1 antibody or anti-canine PD-L1 antibody
CN112851816B (en) * 2014-09-30 2024-03-08 英特维特国际股份有限公司 PD-L1 antibodies that bind canine PD-L1
TWI595006B (en) * 2014-12-09 2017-08-11 禮納特神經系統科學公司 Anti-pd-1 antibodies and methods of use thereof
JP6635290B2 (en) 2015-09-24 2020-01-22 日本電気硝子株式会社 Glass material and manufacturing method thereof
SG11201908543WA (en) 2017-03-27 2019-10-30 Univ Hokkaido Nat Univ Corp Anti-pd-l1 antibody for detecting pd-l1

Also Published As

Publication number Publication date
RU2758723C2 (en) 2021-11-01
WO2018181064A1 (en) 2018-10-04
US11697686B2 (en) 2023-07-11
BR112019019077A2 (en) 2020-04-22
MY197497A (en) 2023-06-19
PH12019502023A1 (en) 2020-03-16
EP3604539A1 (en) 2020-02-05
MX2019010555A (en) 2019-12-11
KR20190132651A (en) 2019-11-28
JP7036388B2 (en) 2022-03-15
US20200031932A1 (en) 2020-01-30
US10865246B2 (en) 2020-12-15
RU2019130661A (en) 2021-04-28
RU2019130661A3 (en) 2021-04-28
JPWO2018181064A1 (en) 2020-02-27
AU2018242880A1 (en) 2019-10-31
EP3604539A4 (en) 2020-12-23
CN110418842B (en) 2023-05-02
KR102402398B1 (en) 2022-05-25
CN110418842A (en) 2019-11-05
US20210079095A1 (en) 2021-03-18
CA3056045A1 (en) 2018-10-04

Similar Documents

Publication Publication Date Title
PH12019501464A1 (en) Novel anti-human transferrin receptor antibody capable of penetrating blood-brain barrier
MX2023007045A (en) Anti-ctla-4 antibodies and methods of use thereof.
PH12018502623A1 (en) Anti-pd-l1 antibodies and uses thereof
AU2018366199A1 (en) Bispecific and monospecific antibodies using novel anti-PD-1 sequences
MX2019002946A (en) Anti-pd-1(cd279) antibodies.
EA201890302A1 (en) CHEMICAL ANTIGEN RECEPTORS BASED ON SINGLE-DOMAIN ANTIBODIES AND METHODS OF THEIR APPLICATION
MX2019001897A (en) Anti-lag-3 antibody.
SG10201901057UA (en) Anti-pd-l1 antibodies
EA201892587A1 (en) USE OF GLUTAMAT-MODULATING AGENTS TOGETHER WITH IMMUNOTHERAPY FOR CANCER TREATMENT
MX2020005792A (en) Anti-pd-l1/anti-cd47 bispecific antibody with structure like natural antibody and in form of heterodimer and preparation thereof.
AR110321A1 (en) ANTITAU ANTIBODIES AND METHODS OF USE
BR112017009817A2 (en) anti-il-1beta antibodies and methods of use
EP3715373A4 (en) Novel scfv amino acid sequence, chimeric antigen receptor comprising same and application thereof
PH12020551173A1 (en) Anti-pd-l1 antibodies and uses thereof
MX2020003087A (en) Novel anti-cd3epsilon antibodies.
SG11201908543WA (en) Anti-pd-l1 antibody for detecting pd-l1
NZ627260A (en) Cx3cr1-binding polypeptides
WO2020051333A8 (en) Anti-avb8 antibodies and compositions and uses thereof
MX2017005642A (en) Anti-ang2 antibodies and methods of use.
NZ728981A (en) Anti-ceramide antibodies
PH12017500699A1 (en) Antibodies that bind to ccr6 and their uses
CR20180515A (en) ANTI-BASIGIN HUMANIZED ANTIBODIES AND USE OF THE SAME
EA202092508A1 (en) COMPOSITIONS BASED ON ANTIBODIES TO HUMAN PD-L1
MY181914A (en) Novel anti-human ig? antibody
MX2019001841A (en) Anti-pd-1 antibody.